News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 19, 2024

Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

Author(s)Derek van Amerongen, MD, MS, Soeren Mattke, MD, DSc, B. Joy Snider, MD, PhD

The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.

Episodes in this series

A panel of 5 experts on Alzheimer disease

EP. 1 The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS

EP. 2 Recent Insights into the Pathophysiology of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 3 Genetic Aspects of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 4 The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 5 Potential Consequences of Early Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 6 Criteria for Diagnosing Alzheimer Disease and the Role of Testing

A panel of experts on Alzheimer's disease

EP. 7 Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 8 Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 9 Clinical Decision-Making for Alzheimer Disease Management

A panel of experts on Alzheimer's disease

EP. 10 Cost, Value, and Affordability of Treatment for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 11 Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

A panel of 5 experts on Alzheimer disease

EP. 12 Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

A panel of 5 experts on Alzheimer disease

EP. 13 Payer Coverage Considerations for New Treatments for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 14 Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

Video content above is prompted by the following question(s):

Could you discuss disease modifying and other therapies for Alzheimer disease that are currently in development?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

MRI of the brain | Image Credit: DedMityay - stock.adobe.com

MASLD, MASH Linked to Higher Mild Cognitive Impairment Risk, Lower Dementia Odds

ByBrooke McCormick

July 30th 2026

Brain scan | Image credit: merydolla - stock.adobe.com

Frailty May Signal Elevated Risk of Cognitive Impairment in CKD

ByBrooke McCormick

July 29th 2026

Remote patient monitoring | Image credit: AndSus - stock.adobe.com

Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

BySkylar Jeremias

July 15th 2026

FDA Approval. | Image credit: @ittawit.21_AdobeStock.jpeg

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

BySabrina McCrear

July 14th 2026

Adam Spira, PhD, MA

Multidimensional Sleep Health Linked to Vascular Dementia Risk in Aging Adults: Adam Spira, PhD, MA

ByPearl Steinzor,Adam Spira, PhD, MA

June 17th 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access